Zobrazeno 1 - 10
of 67
pro vyhledávání: '"Leland J, Yee"'
Autor:
Young-Suk Lim, Henry L.Y. Chan, Sang Hoon Ahn, Wai Kay Seto, Qin Ning, Kosh Agarwal, Harry L.A. Janssen, Calvin Q. Pan, Wan Long Chuang, Namiki Izumi, Scott Fung, Shalimar, Maurizia Brunetto, Aric Josun Hui, Ting-Tsung Chang, Seng Gee Lim, Frida Abramov, John F. Flaherty, Hongyuan Wang, Leland J. Yee, Jia-Horng Kao, Edward Gane, Jinlin Hou, Maria Buti
Publikováno v:
JHEP Reports, Vol 5, Iss 10, Pp 100847- (2023)
Background & Aims: Antiviral therapy may attenuate the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to explore how tenofovir alafenamide (TAF) and tenofovir disoproxil fumarate (TDF) affect HCC risk in p
Externí odkaz:
https://doaj.org/article/6fa5ef22c05d4c2b921cc10c1111b3f7
Autor:
Young-Suk Lim, W. Ray Kim, Douglas Dieterich, Jia-Horng Kao, John F. Flaherty, Leland J. Yee, Lewis R. Roberts, Homie Razavi, Patrick T. F. Kennedy
Publikováno v:
Viruses, Vol 15, Iss 4, p 997 (2023)
Chronic hepatitis B (CHB) is the most common cause of hepatocellular carcinoma (HCC) worldwide. Antiviral treatment reduces the risk of HCC and mortality; nonetheless, globally in 2019, only 2.2% of CHB patients received treatment. Current internatio
Externí odkaz:
https://doaj.org/article/b0f820d04b534e6eae9f1231aec2919b
Autor:
Won-Mook Choi, Terry Cheuk-Fung Yip, Grace Lai-Hung Wong, W. Ray Kim, Leland J. Yee, Craig Brooks-Rooney, Tristan Curteis, Harriet Cant, Chien-Hung Chen, Chi-Yi Chen, Yi-Hsiang Huang, Young-Joo Jin, Dae Won Jun, Jin-Wook Kim, Neung Hwa Park, Cheng-Yuan Peng, Hyun Phil Shin, Jung Woo Shin, Yao-Hsu Yang, Young-Suk Lim
Publikováno v:
Journal of hepatology.
Comparative risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB) receiving tenofovir disoproxil fumarate (TDF) versus entecavir (ETV) remains controversial. This individual patient data (IPD) meta-analysis aimed to compar
Autor:
Young‐Suk Lim, Wai‐Kay Seto, Masayuki Kurosaki, Scott Fung, Jia‐Horng Kao, Jinlin Hou, Stuart C. Gordon, John F. Flaherty, Leland J. Yee, Yang Zhao, Kosh Agarwal, Pietro Lampertico
Publikováno v:
Alimentary pharmacologytherapeutics. 55(8)
The nucleos(t)ide analogues (NAs) entecavir (ETV), tenofovir disoproxil fumarate (TDF) and tenofovir alafenamide (TAF) are preferred treatment options for patients with chronic hepatitis B infection (CHB). However, resistance to ETV has been reported
Autor:
Sang Hoon Ahn, Alnoor Ramji, Scott Fung, Chi-Yi Chen, Hie-Won Hann, Yang Zhao, Shalini Sethi, Wan-Long Chuang, Ho Bae, Leland J. Yee, John F. Flaherty, Carol Yee Kwan Chan, Young-Suk Lim, Xiaoli Ma, Pietro Lampertico, Yoon Jun Kim, Jia-Horng Kao, Anuj Gaggar, Edward Tam, Henry Lik-Yuen Chan, June Sung Lee
Publikováno v:
Clinical Hepatology.
Autor:
Shalini Sethi, Belinda Jump, John F. Flaherty, Carol Yee Kwan Chan, Jia-Horng Kao, Tuan Trong Nguyen, Sang Hoon Ahn, George Y. Wu, Leland J. Yee, Fung Scott, Anuj Gaggar, Seung Woon Paik, Hie-Won Hann, Huy N. Trinh
Publikováno v:
Abstracts.
Background In a recent Phase 3 study (Study 4018) in HBV patients suppressed on TDF treatment, switching to TAF demonstrated non-inferior efficacy to continued TDF with superior bone and renal safety at Week 48. This study is to assess the safety and
Autor:
George Y. Wu, Young-Suk Lim, Scott Fung, Mandana Khalili, Leland J. Yee, Anuj Gaggar, John F. Flaherty, Edward Tam, Sang Hoon Ahn, Ho S. Bae, Yang Liu, Patricia Halton, Pietro Lampertico, Jia-Horng Kao, Xiaoli Ma, Maria Buti, Alnoor Ramji, Kosh Agarwal, Henry Chan, Hie-Won Hann
Publikováno v:
American Journal of Gastroenterology. 115:S543-S543
Autor:
Susanna K. Tan, Shuyuan Mo, John F. Flaherty, Chi-Yi Chen, Pietro Lampertico, Wan-Long Chuang, Sarjita Naik, Anuj Gaggar, Ho Bae, Leland J. Yee, Syed-Mohammed Jafri, Carla S. Coffin, Harry L.A. Janssen, Young-Suk Lim, Claire Fournier, Jeong Heo, Huy N. Trinh
Publikováno v:
Gastroenterology. 158:S-1319
Autor:
John F. Flaherty, Scott Fung, Thomas Berg, Leland J. Yee, Eduardo B. Martins, Terry M. Therneau, Selim Gürel, Ira M. Jacobson, Maria Buti, Rohit Loomba, W. Ray Kim, Phillip Dinh, Raul Aguilar Schall, Patrick Marcellin
Publikováno v:
Cancer. 121:3631-3638
BACKGROUND Efficacy trials have shown that antiviral therapy improves the outcomes of patients with chronic hepatitis B virus (HBV) infection. However, prospective data regarding the effect of antiviral therapy on the incidence of hepatocellular carc
Autor:
Geoffrey Dusheiko, Scott Fung, Eduardo B. Martins, Stuart C. Gordon, Kathryn M. Kitrinos, John F. Flaherty, Robert Flisiak, Leland J. Yee, Vinod K. Rustgi, Maria Buti, Patrick Marcellin, Andrzej Horban, Zahary Krastev, Phillip Dinh, Edward Gane, Ira M. Jacobson, Jörg Petersen, Jan Sperl, Huy N. Trinh
Publikováno v:
Liver International. 35:422-428
Background & Aims We evaluated the antiviral response of Asian or Pacific Islander (API) patients with chronic hepatitis B (CHB) who had baseline high viral load (HVL), defined as pre-treatment hepatitis B virus (HBV) DNA ≥9 log10 copies/ml, follow